A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.Evan Rosenbaum, Sandra P. D’Angelo, Ciara M. Kelly et al.|Journal of Clinical Oncology|2021Cited by 12